

Published in final edited form as:

*Mol Cell*. 2011 August 19; 43(4): 561–571. doi:10.1016/j.molcel.2011.05.037.

## The CDG1 Kinase Mediates Brassinosteroid Signal Transduction from BRI1 Receptor Kinase to BSU1 Phosphatase and GSK3-like Kinase BIN2

Tae-Wuk Kim<sup>1</sup>, Shenheng Guan<sup>2</sup>, Alma L. Burlingame<sup>2</sup>, and Zhi-Yong Wang<sup>1,\*</sup>

<sup>1</sup>Department of Plant Biology, Carnegie Institution for Science, Stanford, CA 94305

<sup>2</sup>Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94143

### SUMMARY

The brassinosteroid (BR) signaling pathway includes two receptor-like kinases (BRI1, BAK1), a plasma membrane-associated kinase (BSK1), two phosphatases (BSU1 and PP2A), a GSK3-like kinase (BIN2), and two homologous transcription factors (BZR1 and BES1/BZR2). But the mechanisms of signal relay are not fully understood. Here we show that a receptor-like cytoplasmic kinase named CDG1 mediates signal transduction from BRI1 to BSU1. Transgenic experiments confirm that CDG1 and its homolog CDL1 positively regulate BR signaling and plant growth. Mass spectrometry analysis identified BRI1 phosphorylation sites in CDG1, and CDG1 phosphorylation sites in BSU1. Mutations of these phosphorylation sites compromised the BR signaling functions. The results demonstrate that BRI1 phosphorylates Ser234 to activate CDG1 kinase, and CDG1 in turn phosphorylates Ser764 to activate BSU1, which inactivates BIN2 by dephosphorylating Tyr200 of BIN2. This study thus demonstrates a complete phosphorylation/dephosphorylation cascade linking a steroid-activated receptor kinase to a GSK3-like kinase in plants.

### INTRODUCTION

Signal transduction mediated by membrane-bound receptor-like kinases (RLKs) is an important regulation mechanism for all cellular organisms, particularly for plants, which rely on signal transduction for development and adaptation to the environment. There are over 400 genes encoding RLKs in *Arabidopsis* and over 600 in rice (Shiu et al., 2004). Studies of a small number of these RLKs demonstrated important functions in a wide range of processes, including hormone responses, development, cell-cell communication, and defense against pathogens (De Smet et al., 2009; Tor et al., 2009). One of the best-studied RLK signaling pathways in plants is the BRI1 receptor kinase pathway, which transduces the brassinosteroid (BR) signal (Kim and Wang, 2010).

BR is a steroidal hormone that regulates a wide range of developmental processes in plants (Clouse and Sasse, 1998). BR-deficient and BR-insensitive mutants show pleiotropic defects including extreme dwarfism, male sterility, delayed senescence, and constitutive photomorphogenesis in the dark (Li et al., 1996). In contrast to animal steroid receptors,

© 2011 Elsevier Inc. All rights reserved.

\*To whom correspondence should be addressed. Tel: 650-325-1521 Ext. 205; Fax: 650-325-6857; zywang24@stanford.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

which are nuclear transcription factors, the BR receptor BRI1 is one of the 230 members of the leucine-rich repeat receptor-like kinases (LRR-RLK) in *Arabidopsis* (Li and Chory, 1997). BRI1 perceives BR through its extracellular domain and transduces the signal through its cytoplasmic kinase domain (Kinoshita et al., 2005; Wang et al., 2001). In the absence of BR, BRI1 kinase is inactive, while BIN2, a GSK3-like kinase (Li and Nam, 2002), phosphorylates and inactivates two homologous nuclear transcription factors called BZR1 and BZR2 (also named BES1) to repress BR-responsive gene expression (Gampala et al., 2007; He et al., 2002; Vert and Chory, 2006; Wang et al., 2002; Yin et al., 2002). BR binding to BRI1's extracellular domain activates its kinase activity by inducing association and transphosphorylation with the co-receptor BAK1, another LRR-RLK (Li et al., 2002; Nam and Li, 2002; Wang and Chory, 2006; Wang et al., 2008). Activation of BRI1 also involves dissociation of BRI1 KINASE INHIBITOR 1 (BKII) caused by tyrosine phosphorylation (Jaillais et al., 2011; Wang and Chory, 2006). Activated BRI1 kinase initiates a signaling cascade that leads to inactivation of BIN2 and dephosphorylation of BZR1 and BZR2 by the protein phosphatase 2A (Tang et al., 2011). Dephosphorylated BZR1 and BZR2 accumulate in the nucleus and regulate the expression of BR target genes (He et al., 2005; Sun et al., 2010; Yin et al., 2005; Yu et al., 2011).

Signal transduction from BRI1 to BIN2 involves the BR-SIGNALING KINASE 1 (BSK1) (Tang et al., 2008) and the BRI1 SUPPRESSOR 1 (BSU1) phosphatase (Kim et al., 2009; Mora-Garcia et al., 2004), but the mechanisms of signal relay are not fully understood. BSK1 is a member of the receptor-like cytoplasmic kinase (RLCK) XII family (Tang et al., 2008). RLCKs are homologous to transmembrane RLKs but contain no extracellular or transmembrane domains (Shiu et al., 2004). BSK1 is localized at the plasma membrane and is phosphorylated at Ser230 by BRI1 upon BR treatment (Tang et al., 2008). Ser230 phosphorylation increases BSK1 binding to BSU1 (Kim et al., 2009; Tang et al., 2008). BSU1 inactivates BIN2 by dephosphorylating its Tyr200 residue, BR treatment enhances BSU1 dephosphorylation of BIN2, but the mechanism of BSU1 activation remains unclear (Kim et al., 2009).

A previous study suggested that Constitutive Differential Growth1 (CDG1), a member of the RLCK VIIc family, is involved in activation of BR signaling (Muto et al., 2004). The *cdg1-D* mutant, overexpressing CDG1 due to activation tagging mutagenesis, showed insensitivity to BR biosynthetic inhibitor brassinazole (BRZ) and altered expression of BR-responsive genes consistent with activation of the BR signaling pathway (Muto et al., 2004). However, the biochemical function of CDG1 in BR signaling has not been studied.

In this study, we show that CDG1 and its homolog CDL1 mediate signal transduction from BRI1 to BSU1. CDG1 phosphorylates the Ser764 residue in BSU1's phosphatase domain to increase BSU1's ability to dephosphorylate Tyr200 residue of BIN2. CDG1 is phosphorylated by BRI1 at Ser44, Ser47, and Ser234, and mutations of these phosphorylation sites compromised CDG1's ability to activate BR signaling in vivo. In vitro assays demonstrate that BSU1 and either CDG1 or BSK1 are the minimum components required for signal transduction from BRI1 to BIN2. Our results therefore establish a complete phosphorylation/dephosphorylation cascade that mediates the inactivation of a GSK3 kinase by a steroid-activated receptor kinase in plants (Figure S1).

## RESULTS

### CDG1 Positively Regulates BR Signal Transduction

To elucidate the functional role of CDG1 in BR signaling, we first transformed BR-deficient and BR-insensitive mutants with a CDG1 overexpression (CDG1-ox) construct. Overexpression of CDG1 partially suppressed the phenotypes of the BR-deficient *det2*

mutant (Figure S2A) and the BR receptor *bri1-5* mutant (Figures 1A–1C). Similar to the *bzr1-1D* mutant, in which the *bzr1-1D* protein is activated by increased interaction with PP2A (Tang et al., 2011; Wang et al., 2002), the *CDG1-ox* plants showed reduced sensitivity to the BR-biosynthetic inhibitor BRZ (Figure 1D), reduced expression of the BR-repressed BZR1-target gene *DWF4*, increased expression of BR-induced BZR1-target gene *SAUR-AC1* (Figure 1E), and accumulation of dephosphorylated BZR1 proteins (Figure 1F). Light-grown plants overexpressing high levels of CDG1 showed smaller sizes with curled leaves and elongated petioles (Figure 1B and 1F), reminiscent to plants grown on high concentrations of BR or overexpressing the dominant allele of *bzr1-1D*. These results demonstrate that overexpression of CDG1 activates the BR signal transduction pathway in *Arabidopsis*.

### CDG1 and CDL1 are Plasma Membrane Proteins that Positively Regulate BR Signaling

When expressed in either stably transformed *Arabidopsis* plants or transiently transformed tobacco cells, CDG1-YFP was only observed at the cell surface, independent of BR treatment (Figure 2A and S2B). CDG1 has two cysteine residues in its N-terminal region predicted to be palmitoylation sites (Figure 2A). Substitution of these cysteine residues to alanine (CDG1-C4,6A-YFP) resulted in nuclear localization of the CDG1 protein in both *Arabidopsis* and tobacco cells (Figure 2A and Figure S2B), suggesting that CDG1 is anchored to the plasma membrane by palmitoylation. The transgenic plants overexpressing CDG1-C4,6A-YFP showed no phenotypes (Figure 2B), indicating that plasma membrane localization is required for CDG1 to function in BR signal transduction.

The closest *Arabidopsis* homolog of CDG1 (CDG1-like1, CDL1) shares 65% amino acid sequence identity with CDG1. Like CDG1, CDL1-YFP was also detected in the plasma membrane (Figure S2C) and overexpression of CDL1 suppressed the *bri1-5* mutant phenotype (Figure S2D), suggesting a similar function in activating BR signaling. A CDG1 promoter-GUS reporter gene indicates that CDG1 is expressed at a very low level in vegetative tissues but at high levels in the stamen and pollen of flower (Figure 2C). By contrast, CDL1 promoter-GUS expression was ubiquitously detected in reproductive and vegetative tissues (Figure 2C). Consistent with their expression patterns, the *cdg1* loss-of-function mutant (*cdg1-2*), which was isolated as an intragenic suppressor of *cdg1-D* (Muto et al., 2004), showed no obvious phenotypes, whereas the *cdl1-1* knockout mutant showed reduced sensitivity to BR and enhanced sensitivity to BRZ (Figures 2D and 2E). In addition, *cdg1-2/cdl1-1* double mutant showed stronger BL-insensitivity and enhanced BRZ-sensitivity compared to *cdg1-2* or *cdl1-1* single mutant (Figures 2D and 2E). However, the phenotypes of *cdg1-2/cdl1-1* is still very subtle compared to typical BR-insensitive mutants such as *bri1-5* or *bin2-1*, likely due to redundant functions of other homologous RLCKs. Interestingly, the expression pattern of CDG1 is similar to that of BSU1, and CDL1 is expressed broadly similar to BSL1 (Figure S2E).

### CDG1 Acts Upstream of BIN2 in the BR Signaling Pathway

To analyze the genetic interaction of CDG1 with BR signaling components, we crossed the CDG1 overexpression plant into the BR-insensitive mutants *bri1-116* (null allele) and *bin2-1* (gain-of-function allele). Overexpression of CDG1 partly suppressed the phenotype of *bri1-116* but did not suppress the phenotype of *bin2-1* homozygous mutant (Figures 3A and 3B), indicating that CDG1 acts upstream of BIN2 and downstream of BRI1. Notably, the phenotypes of CDG1-overexpressors were very similar to those of BSU1-overexpression plants, such as bending in stem-branch junction, flattened shape of silique, and pale green and slender leaves (Figures 3C–3E, Figure S3A). In addition, plants overexpressing both CDG1-YFP and BSU1-myc showed dramatically enhanced phenotypes of leaf twisting and BRZ resistance compared to plants expressing either CDG1-YFP or BSU1-myc alone

(Figures 3E and 3F, Figure S3B), suggesting that CDG1 and BSU1 function together in BR signaling.

### CDG1 Interacts with BSU1 in vitro and in vivo

We tested whether CDG1 and BSU1 directly interact with each other. In vitro overlay assays showed that GST-CDG1 in a gel blot can be detected by MBP-BSU1 and anti-MBP antibody (Figure 4A). In yeast-two hybrid assays, CDG1 strongly interacts with BSU1 and weakly with BSU1 homolog, BSL1 (BSU1-like 1). However, CDL1 strongly interacts with both BSU1 and BSL1 (Figure 4B). Furthermore, Bimolecular Fluorescence Complementation (BiFC) assays showed strong fluorescence signal in tobacco epidermal cells co-expressing CDG1 or CDL1 fused to N-terminal half of the yellow fluorescence protein (nYFP) and BSU1 or BSL1 fused to C-terminal half of YFP (cYFP), whereas tobacco cells co-expressing BIN2-cYFP, and CDG1-nYFP or CDL1-nYFP showed no fluorescence signal (Figure 4C), indicating that CDG1/CDL1 interacts with BSU1/BSL1 but not BIN2. Consistent with the yeast-two hybrid data, in vivo interaction between CDG1 and BSL1 in tobacco cells was very weak, whereas CDL1 strongly interacted with both BSU1 and BSL1 (Figures 4B and 4C). We further confirmed in vivo interaction between BSU1 and CDG1 or CDL1 using co-immunoprecipitation assays. BSU1-myc protein was immunoprecipitated by anti-GFP antibody from tobacco cells co-expressing BSU1-myc and CDG1-YFP or CDL1-YFP (Figure S3C) or *Arabidopsis* co-expressing BSU1-myc and CDG1-YFP (Figure 4D). BR treatment slightly increased the amount of BSU1-myc co-immunoprecipitated with CDG1-YFP in transgenic *Arabidopsis* (Figure 4D), suggesting that BR signaling increases the interaction between CDG1 and BSU1.

### CDG1 Activates BSU1 by Phosphorylating its Serine 764 Residue

Both CDG1 and CDL1 showed strong autophosphorylation activity in vitro (Figure 5A, Figures S4A and S4E). We created kinase-inactive CDG1 harboring a mutation (Y147G) in the ATP-binding pocket of CDG1 kinase. This mutation abolished CDG1 kinase activity in vitro and the typical CDG1 overexpression phenotypes in transgenic plants (Figures S4A–S4D). These results indicate that the kinase activity of CDG1 is required for CDG1 to effectively activate BR response. Thus, we hypothesized that CDG1 modulates BSU1 activity through phosphorylation. Indeed, in vitro kinase assays showed that CDG1 phosphorylated BSU1 (Figure 5A). Consistent with the different strength of interactions observed in yeast two-hybrid and BiFC assays (Figures 4B and 4C), CDG1 only weakly phosphorylated three other BSU1 homologs (BSL1, BSL2 and BSL3) (Figure 5A), and CDL1 phosphorylated both BSU1 and BSL1 equally well in vitro (Figure S4E).

We next examined whether BR treatment induces phosphorylation of BSU1 in plant cells. The BSU1-myc transgenic *Arabidopsis* plants were treated with BR, and the BSU1-myc protein was analyzed by two-dimensional gel electrophoresis followed by immunoblotting. The results show that the acidic spots of BSU1-myc protein were increased and the basic spots were decreased after BR treatment, suggesting that BSU1 is phosphorylated upon BR signaling (Figure 5B). We then performed mass spectrometric analysis of the in vivo phosphorylation sites of BSU1 using proteins immunoprecipitated from transgenic *Arabidopsis*, and we identified three in vivo phosphorylation sites (serine 395, 444 and 764) of BSU1 (Figure 5C and Figures S5A–S5C). The Serine 444 and 764 residues were also identified in the three BSU1 homologs (BSL1, BSL2 and BSL3) by a recent proteomic study (Benschop et al., 2007; Sugiyama et al., 2008). Substitution of Ser764 to alanine (BSU1-S764A) greatly reduced the phosphorylation of BSU1 by both CDG1 and CDL1 (Figure 5D and Figure S5D), whereas mutations of Ser395 and 444 had little effect, indicating that both CDG1 and CDL1 specifically phosphorylate the Ser764 residue of BSU1.

BSU1 contains an N-terminal Kelch-repeat domain and a C-terminal phosphatase domain, and the Ser764 residue is in the C-terminal region of the phosphatase domain (Mora-Garcia et al., 2004). In vitro overlay assay indicated that BIN2 interacts with the C-terminal phosphatase domain but not with the N-terminal Kelch-repeat domain of BSU1 (Figure S5E). CDG1 phosphorylation increased BSU1 binding to BIN2, but had little effect on BSU1-S764A binding to BIN2 (Figure 5E). Furthermore, CDG1 phosphorylation strongly enhanced the ability of BSU1 but not of BSU1-S764A to dephosphorylate Tyr200 of BIN2 (Figure 5F). However, CDG1 did not increase BSU1 dephosphorylation of the artificial substrate phospho-myelin basic protein (Figure S5F). These results indicate that CDG1 phosphorylates BSU1 Ser764 to promote BSU1 dephosphorylation of BIN2, most likely by enhancing BSU1-BIN2 interaction rather than increasing the catalytic activity of BSU1.

To further confirm the functional importance of Ser764 phosphorylation of BSU1, we overexpressed wild-type BSU1 and BSU1-S764A mutant in *bri1-5*. The percentage of transgenic plants showing phenotypic suppression was significantly lower in the T1 population transformed with BSU1-S764A than that transformed with the wild-type BSU1 (Figure 5G and Figure S5G). While the S764A mutation significantly reduced the efficiency of BSU1 to suppress *bri1-5*, some transgenic plants showed strong phenotype suppression, suggesting that unphosphorylated BSU1 has some basal activity. Taken together, our results strongly suggest that CDG1 phosphorylation of Ser764 of BSU1 increases its interaction with and dephosphorylation of BIN2, which inactivates BIN2 and stops the phosphorylation of BZR1.

### CDG1 is Activated by BRI1 Phosphorylation

The plasma membrane localization and action upstream of BSU1 suggest that CDG1 may act directly downstream of BRI1. We thus tested BRI1-CDG1 interaction. As shown in Figure 6A, strong BiFC fluorescence signal was observed in the tobacco epidermal cells co-expressing BRI1-nYFP and CDG1-cYFP, whereas no signal was detected in cells co-expressing nYFP fusion of a receptor kinase unrelated to BR signaling (At5g49760) and CDG1-cYFP. In yeast two-hybrid assays, CDG1 interacted with the BRI1 kinase domain, but not with the BAK1 kinase domain, whereas BRI1 kinase domain interacted with neither BSU1 nor BSL1 (Figure S6A). In addition, CDG1-myc was co-immunoprecipitated by anti-GFP antibody from the microsomal fraction of transgenic *Arabidopsis* co-expressing BRI1-GFP and CDG1-myc (Figure 6B). These results indicate that BRI1 directly interacts with CDG1.

In vitro kinase assay demonstrated that a kinase-inactive CDG1 mutant protein (CDG1-Y147G) was strongly phosphorylated by the BRI1 kinase domain but not by the BAK1 kinase domain, relative to their autophosphorylation activity (Figure 6C). Thus, we performed mass spectrometry analysis of the kinase-inactive CDG1-Y147G phosphorylated by BRI1 kinase, and identified two serine residues (Ser44 and Ser47) in the N-terminal region and one serine residue (Ser234) in the activation loop domain of CDG1 as BRI1-phosphorylation sites (Figure 6D and Figures S6B–S6D). All three residues are also conserved in CDL1 protein. In particular, Ser234 of CDG1 corresponds to the BRI1 phosphorylation site (Ser230) of BSK1 (Figure S7A). Mutations of both Ser44 and Ser47 (CDG1-S44,47A) or only Ser234 (CDG1-S234A) to alanine significantly reduced BRI1 transphosphorylation of CDG1 (Figure 6E and Figure S7B), confirming that BRI1 phosphorylates CDG1 at Ser 44, 47 and Ser234.

To evaluate biological importance of BRI1 phosphorylation of CDG1 in BR signaling, we overexpressed wild-type CDG1 and mutant CDG1 containing mutations of the BRI1 phosphorylation sites in *bri1-5*. The frequency for phenotypic suppression of the *bri1-5* mutant was greatly reduced in transgenic plants transformed with the *35S::CDG1-S234A*

construct, and slightly reduced in plants transformed with the *35S::CDG1-S44,47A* construct, compared to those overexpressing wild-type CDG1 (Figure 1B and Figure 6F). The results suggest that BRI1 phosphorylation of CDG1 at Ser234 is a major mechanism of CDG1 activation, whereas phosphorylation in the N-terminal region also contributes to the activation.

### The Signaling Cascade of Phosphorylation and Dephosphorylation from BRI1 to BIN2

To understand the mechanism of CDG1 activation by BRI1, we further tested the effect of BRI1 phosphorylation on CDG1 binding to BSU1. Pre-incubation of CDG1 with BRI1 and ATP increased CDG1 binding to and phosphorylation of BSU1 in vitro (Figures 7A and 7B), suggesting that BRI1 phosphorylation of CDG1 activates CDG1 phosphorylation of BSU1.

The above results demonstrate key steps of BR signal transduction, including BRI1 phosphorylation/activation of CDG1, CDG1 phosphorylation of BSU1, and BSU1 dephosphorylation/inactivation of BIN2. To confirm such a signaling cascade in the test tube, we performed in vitro BIN2 Tyr200 dephosphorylation assays using BSU1 in the presence of CDG1, BSK1 or BRI1 (Figure 7C). Under our experimental conditions, incubation with BSU1 reduced the Tyr200 phosphorylation of BIN2 by about 20%. When wild-type BRI1 kinase was added without CDG1 or BSK1, there was no significant effect on BSU1 dephosphorylation of BIN2. BSK1 also failed to enhance BIN2 dephosphorylation without active BRI1. However, when BRI1 kinase was added together with BSK1, BIN2 dephosphorylation increased to about 50%. However, BSK1 pre-incubated with BRI1 kinase and ATP still failed to phosphorylate BSU1 (Figure S7C). When CDG1 was added without active BRI1, BIN2 Tyr200 phosphorylation was reduced by about 60%, and the dephosphorylation was further enhanced when active BRI1 kinase was added together (Figure 7C). However, when CDG1 and BSK1 were added together, no further increase of BIN2 dephosphorylation was observed, possibly BSU1 was fully activated under this condition. These results demonstrate that BSU1 can be activated by BRI1 through either BSK1 or CDG1. BSU1 activation by BSK1 requires BRI1 kinase activity, whereas activation by CDG1 does not require BRI1 but is enhanced by BRI1. The results identify BSU1 and either CDG1 or BSK1 as the minimum set of components for transducing the signal from the receptor kinase BRI1 to the GSK3-like kinase BIN2.

We further examined the relationship between CDG1 and BSKs member. Of BSK family members, the *bsk3* mutant is known to display strong BL-insensitivity and BRZ-hypersensitivity (Tang et al., 2008). Therefore, we introduced CDG1-ox into the *bsk3* mutant to test if CDG1 and BSK3 are functionally redundant or act independently of each other. In the root inhibition assay by BL, *CDG1-ox* plants were more sensitive than WT while the *bsk3* mutant showed strong BL-insensitivity. Interestingly, BL-insensitivity of the *bsk3* mutant was decreased by CDG1 overexpression as CDG1-ox did in WT (Figure S7D). However, importantly, *CDG1-ox/bsk3* double mutant still showed considerable BL-insensitivity compared to WT (Figure S7D), suggesting that CDG1 overexpression is not able to fully complement the phenotype of the *bsk3* mutant. Same phenomenon was also observed in hypocotyl elongation of seedlings grown on BRZ medium in the dark (Figure S7E). These results suggest that CDG1 and BSK3 may act independently.

## DISCUSSION

Combinations of genetic and proteomic studies have established the BR signaling pathway as one of the best understood signal transduction pathways in plants. In particular the BR signaling pathway serves as a model for understanding the large numbers of receptor kinase pathways in plants. In this study, we further complete this signaling pathway by showing the

function of CDG1 in transducing BR signal from the BRI1 receptor kinase to the BSU1 phosphatase and the BIN2 kinase. Our results reveal mechanistic details of signaling between these components. Together with previous studies (Kim and Wang, 2010; Tang et al., 2011), this study provides the BR signaling pathway with detailed mechanisms of each step of signal relay: BR binding to the extracellular domain of BRI1 induces dimerization between BRI1 and BAK1 and disassociation of BKI1, causing full activation of the BRI1 kinase; BRI1 phosphorylates BSK1 at Ser230 or CDG1 at Ser234 to promote interaction with BSU1; CDG1 phosphorylates BSU1 at Ser764 to increase BSU1 binding to BIN2; BSU1 dephosphorylates BIN2 at Tyr200 to inactivate BIN2 and stop the phosphorylation of BZR1. In the mean time, PP2A directly interacts with and dephosphorylates phospho-BZR1 (Figure S1) (Tang et al., 2011). Dephosphorylated BZR1 translocates to the nucleus and regulates thousands of BR target genes (Sun et al., 2010; Yu et al., 2011).

### CDG1 mediates BRI1 activation of BSU1

Our analysis of genetic interactions indicated that CDG1 acts downstream of BRI1 and upstream of BIN2. We previously showed that BSU1 also acts upstream of BIN2. The direct interactions of CDG1 with BRI1 and BSU1 indicate that CDG1 acts immediately downstream of BRI1 and thus upstream of BSU1. We further identified three phosphorylated residues of BSU1 (Ser395, Ser444, and Ser764) *in vivo* and determined that Ser764 is a major site for CDG1 phosphorylation and activation of BSU1. CDG1 phosphorylation of the wild-type BSU1 increased its binding and dephosphorylation of BIN2, and this effect of CDG1 is abolished by the S764A mutation of BSU1 (Figures 5E and 5F). Consistent with the *in vitro* data, expression of the mutant BSU1-S764A was less effective in suppressing the *bri1-5* phenotypes compared with the wild-type BSU1 (Figure 5G). These results demonstrate that CDG1 activates BSU1 by phosphorylation of BSU1 Ser764. Interestingly, CDG1 phosphorylation of BSU1 had no significant effect on BSU1 dephosphorylation of an artificial substrate, suggesting that CDG1 promotes BIN2 Tyrosine dephosphorylation by increasing BSU1-BIN2 binding rather than BSU1's catalytic activity.

While phosphorylation of Ser764 seems essential for CDG1 activation of BSU1, BSU1 seems to have a basal level of BIN2-binding and dephosphorylation activity without CDG1 phosphorylation. The mutant BSU1-S764A showed basal levels of *in vitro* binding and dephosphorylation of BIN2 independent of CDG1 treatment. Expression of BSU1-S764A also suppressed the phenotype of the *bri1-5* mutant, although at a reduced efficiency compared to wild-type BSU1 (Figures 5E–5G). On the other hand, BSU1 is also phosphorylated *in vivo* at two additional residues, Ser395 and Ser444, which might contribute to regulation of BSU1 *in vivo*. Unlike Ser764, mutations of Ser399 and Ser444 to alanine did not significantly reduce CDG1 phosphorylation of BSU1 *in vitro*, suggesting that these residues are not phosphorylated by CDG1. What kinase mediates the phosphorylation of these residues and how they affect BSU1 function remain to be studied.

We showed that BRI1 directly phosphorylates CDG1. Mass spectrometry analysis identified three BRI1 phosphorylation sites of CDG1 (Ser44, 47 and 234). Mutations of these sites (CDG1-S44,47A or CDG1-S234A) decreased the *in vitro* phosphorylation by BRI1, as well as *in vivo* phenotypic suppression of *bri1-5* by CDG1 overexpression (Figure 6D). The different severities of *bri1*-suppression phenotype suggest that phosphorylation of Ser234 plays a major role in activating CDG1, whereas Ser44 and 47 have a smaller contribution. *In vitro* assays indicated that BRI1 phosphorylation increases CDG1 binding to BSU1. BRI1 phosphorylation may also increase the kinase activity of CDG1, but this is difficult to distinguish experimentally from BRI1's own kinase activity.

## Parallel Functions of CDG1, BSK1, and Their Homologs

BSK1 and CDG1 are members of two distinct RLCK subfamilies (RLCK XII and VIIc, respectively), but they seem to play similar role in BR signaling. The Ser234 of CDG1 is equivalent to Ser230 of BSK1, which is phosphorylated by BRI1 to promote binding to BSU1 (Tang et al., 2008). However, while CDG1 activates BSU1 by phosphorylating Ser764, it is unclear how BSK1 activates BSU1. BSK1 lacks some of the invariant residues considered essential for kinase activity, such as the aspartate of the canonical DFG motif in domain VII, and no kinase activity has been detected for BSK1 or its homologs in vitro (Bayer et al., 2009; Castells and Casacuberta, 2007; Tang et al., 2008). Atypical kinases defective in catalytic activity can mediate signal transduction through protein-protein interaction. For example, the ErbB3 receptor, a member of epidermal growth factor receptor (EGFR) family of receptor tyrosine-protein kinases, is kinase-impaired, but is phosphorylated by other members of the EGFR proteins and acts as docking sites for downstream signaling components (Kim et al., 1998). The BRI1-phosphorylated BSK1 may function as a scaffold or docking platform that brings BSU1 together with BRI1 or CDG1 for phosphorylation or together with BIN2 to facilitate dephosphorylation and inactivation of BIN2. Alternatively, BSK1 may acquire kinase activity upon phosphorylation by BRI1 or other kinases in vivo, although BRI1 phosphorylation of BSK1 did not confer BSK1 phosphorylation activity of BSU1 in vitro (Figure S7C).

While BSK1 requires BRI1 activation, CDG1 itself shows kinase activity and considerable ability to activate BSU1 independent of BRI1, though this ability is further enhanced by BRI1 (Figure 5F and Figure 7C). Recombinant CDG1 could autophosphorylate Ser234 (Figure S7F), and it bound to BSU1 more strongly than BSK1 did (Figure S7G). Thus, CDG1 may provide a high basal BR signaling level, whereas BSK1 would provide a more effective switch controlled by the level of BR. It is possible that BSK1 and CDG1 function in different cells to provide different BR sensitivities, or they may also act as two independent parallel mechanisms or act together cooperatively in certain cells. Parallel components mediating the same step of signal transduction has been observed in mammals. For example, insulin signaling activates PKB (Protein kinase B/Akt) to suppress GSK3 activity. PKB is activated by both 3-phosphoinositide-dependent protein kinase 1 (PDK1) and mammalian target of rapamycin protein kinase c2 (mTORc2) through phosphorylation on different amino acid of PKB (Cybulski and Hall, 2009).

Different members of each of the CDG1, BSK1, and BSU1 families appear to perform similar biochemical functions but act in different tissues and have different interaction specificities. CDG1 and BSU1 are highly expressed in pollen but very weakly in vegetative tissues, whereas BSKs, CDL1 and BSL1 showed more ubiquitous expression patterns (Figure S2E), raising a possibility that pairs of members of the two families form tissue-specific signaling modules. Although overexpression of CDG1 and BSU1 causes strong phenotypes during vegetative development, their functions might be restricted to reproductive development in wild-type plants. This possibility is further supported by the higher interaction affinity between co-expressed homologs. The weak phenotype of the *cdg1/cdl1* double mutant suggests that additional homologs may have redundant functions. CDG1 and CDL1 belong to the RLCK VIIc subfamily with 15 members that share 54%–65% amino acid sequence identity (Shiu et al., 2004), among which *At5g13160* (64% sequence identity with CDG1) is expressed broadly like CDL1 and *At5g18610* (63% identity) is expressed highly in pollen similar to CDG1 (<http://bbc.botany.utoronto.ca/efp/cgi-bin/efpWeb.cgi>). The additive effects of CDG1 overexpression and the *bsk3* mutant suggest that they may act in independent parallel pathways, possibly activating different members of the BSU family. We hypothesize that BSKs and CDG1 families may provide not only tissue specific functions but also may act



through independent mechanisms, whereas members within each family can also have distinct or redundant functions.

### RLCKs Mediate Signal Output from Plant RLKs

The functions of BSK1 and CDG1 may represent a general role of RLCKs in transducing signals downstream of transmembrane RLKs. About 150 genes in *Arabidopsis* encode RLCKs (Shiu et al., 2004). In addition to BSK1, CDG1, and their close homologs that function in BR signaling, a small number of other RLCKs have been studied in plants. One of them is SHORT SUSPENSOR (SSP) (Bayer et al., 2009), which is a distant member of the BSK family (BSK12) (Tang et al., 2008). Genetic analysis suggests that SSP acts upstream of the YDA MAP kinase cascade in controlling embryonic development (Bayer et al., 2009). Recently, several RLCK VII members, including PBS1, PBS1-like proteins (PBLs), and BOTRYTIS-INDUCED KINASE 1 (BIK1), were shown to act downstream of multiple immune receptor kinases that detect pathogen-associated molecular patterns (PAMPs) (Lu et al., 2009; Zhang et al., 2010). In particular, BIK1 and PBL1 appear to act downstream of FLS2, the receptor-like kinase perceiving flagellin, in a manner similar to BRI1 regulation of BSK1 and CDG1. BIK1 and PBL1 interact with unstimulated FLS2, and are phosphorylated upon flagellin stimulation and then disassociate from FLS2 (Zhang et al., 2010), which is similar to the BSK1 phosphorylation and dissociation from BRI1 upon BR signaling. CDG1, BIK1, and PBS1 are all members of the RLCK VII subfamily. As such, FLS2 and BRI1 share not only the same co-receptor kinase BAK1 (Li, 2010), but also members of the same RLCK family for downstream signal transduction. Future studies will clarify whether different RLKs use similar or distinct downstream signaling mechanisms in plants.

## EXPERIMENTAL PROCEDURES

### In Vitro Kinase and Phosphatase Assays

Recombinant proteins were expressed in *E. coli* and purified by affinity tags. To test phosphorylation of BSU1 and BSU1 variants by CDG1 or CDL1, 0.5  $\mu$ g of GST-CDG1 or GST-CDL1 was incubated with 2.5  $\mu$ g of MBP-BSU1 or mutant MBP-BSU1 in the kinase buffer (20 mM Tris, pH 7.5, 1 mM MgCl<sub>2</sub>, 100 mM NaCl and 1 mM DTT) containing 100  $\mu$ M ATP and 10  $\mu$ Ci <sup>32</sup>P- $\gamma$ -ATP at 30°C for 3 hrs. To examine whether BRI1 phosphorylates CDG1, GST-CDG1-Y147G, GST-mBRI1-K (Y956G) and GST-mBAK1-K (K317E) were incubated with wild-type kinases according to Tang et al (Tang et al., 2008). Protein phosphorylation was analyzed by SDS-PAGE followed by autoradiography.

To test BSU1 activation by CDG1, MBP-BSU1 protein bound to amylose beads was first incubated with GST-CDG1 and ATP or buffer without GST-CDG1 as control, and GST-CDG1 was removed by washing. The pre-treated MBP-BSU1 beads were then incubated with GST-BIN2, and BIN2 phospho-Tyr200 was analyzed by immunoblotting using the anti-pTyr297/216 GSK3 $\alpha$ / $\beta$  antibody, as described previously (Kim et al., 2009). For the experiment shown in Figure 7C, 0.5  $\mu$ g of GST-CDG1, GST-BSK1, GST-BRI1-K, or GST-mBRI1-K were pre-incubated with MBP or MBP-BSU1 (1  $\mu$ g) in the presence of ATP for 1.5 hour. Then, 0.5  $\mu$ g of BIN2 protein purified using Profinity eXact-tag fusion system (Bio-Rad, Hercules, CA) was added and further incubated for 4 hrs. The proteins were separated on SDS-PAGE gel and the blot was sequentially probed with anti-pTyr297/216 GSK3 $\alpha$ / $\beta$  antibody and anti-BIN2 antibody. The chemiluminescence images were acquired using the Digital FluorChem Q analyzer (Alpha Innotech Corp, San Leandro, CA) and the signal of each band was quantified by ImageQuant 5.2 software (GE healthcare, Sunnyvale, CA).

## Determination of Phosphorylation Sites

Proteins were extracted from leaf tissues of transgenic *Arabidopsis* overexpressing BSU1-YFP using IP buffer (50 mM Tris, pH 7.5, 50 mM NaCl, 300 mM Sucrose, 1% Triton X-100, 1 mM PMSF, 1  $\mu$ M E-64, 1  $\mu$ M bestatin, 1  $\mu$ M pepstatin and 2  $\mu$ M leupeptin) and incubated with anti-GFP antibody bound protein A beads for 1 hr. Beads were washed 5 times with IP buffer containing 0.2% Triton X-100. The proteins were eluted with 2% SDS and separated by SDS-PAGE. After Coomassie Blue staining, the BSU1-YFP gel band was excised and subjected to in-gel trypsin digestion followed by LC-MS/MS analysis.

To identify BRI1 phosphorylation site on CDG1, GST-BRI1-K (5  $\mu$ g) and GST-CDG1-Y147G protein (20  $\mu$ g) were incubated with 100  $\mu$ M ATP in the kinase buffer for 12 hrs at 30°C. The protein solution was subjected to in-solution alkylation/trypsin digestion followed by LC-MS/MS analysis as described previously (Gampala et al., 2007).

## Co-immunoprecipitation

Co-immunoprecipitations were performed as described previously (Kim et al., 2009). Microsomal fraction was prepared by centrifugation at 20,000g and 100,000g for 1 hr. The resulting pellet was resuspended in extraction buffer containing 1% Triton X-100. After centrifugation at 14,000 rpm for 10 min, solubilized proteins were incubated with anti-GFP antibody bound to protein A bead for 1 hr. The beads were washed four times with extraction buffer containing 0.1% Triton X-100 and eluted with SDS sample buffer.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


We thank Dr. Kotaro Yamamoto at Hokkaido University for providing CDG1 overexpression and knockout mutant seeds, and cDNA clone. This study was supported by grants from NSF (IOS 0724688) and NIH (R01GM066258). The UCSF Mass Spectrometry Facility (A.L. Burlingame) was supported by the Biomedical Research Technology Program of the National Center for Research Resources, NIH NCRR (RR001614, RR015804, P41RR019934 and RR012961).

## References

- Bayer M, Nawy T, Giglione C, Galli M, Meinel T, Lukowitz W. Paternal control of embryonic patterning in *Arabidopsis thaliana*. *Science*. 2009; 323:1485–1488. [PubMed: 19286558]
- Benschop JJ, Mohammed S, O'Flaherty M, Heck AJ, Slijper M, Menke FL. Quantitative phosphoproteomics of early elicitor signaling in *Arabidopsis*. *Mol Cell Proteomics*. 2007; 6:1198–1214. [PubMed: 17317660]
- Castells E, Casacuberta JM. Signalling through kinase-defective domains: the prevalence of atypical receptor-like kinases in plants. *J Exp Bot*. 2007; 58:3503–3511. [PubMed: 17951602]
- Clouse SD, Sasse JM. BRASSINOSTEROIDS: Essential Regulators of Plant Growth and Development. *Annu Rev Plant Physiol Plant Mol Biol*. 1998; 49:427–451. [PubMed: 15012241]
- Cybulski N, Hall MN. TOR complex 2: a signaling pathway of its own. *Trends Biochem Sci*. 2009; 34:620–627. [PubMed: 19875293]
- De Smet I, Voss U, Jurgens G, Beeckman T. Receptor-like kinases shape the plant. *Nat Cell Biol*. 2009; 11:1166–1173. [PubMed: 19794500]
- Gampala SS, Kim TW, He JX, Tang W, Deng Z, Bai MY, Guan S, Lalonde S, Sun Y, Gendron JM, et al. An essential role for 14-3-3 proteins in brassinosteroid signal transduction in *Arabidopsis*. *Dev Cell*. 2007; 13:177–189. [PubMed: 17681130]

- He J-X, Gendron MJ, Sun Y, Gampala SSL, Gendron N, Sun CQ, Wang Z-Y. BZR1 is a transcriptional repressor with dual roles in brassinosteroid homeostasis and growth responses. *Science*. 2005; 307:1634–1638. [PubMed: 15681342]
- He JX, Gendron JM, Yang Y, Li J, Wang ZY. The GSK3-like kinase BIN2 phosphorylates and destabilizes BZR1, a positive regulator of the brassinosteroid signaling pathway in Arabidopsis. *Proc Natl Acad Sci U S A*. 2002; 99:10185–10190. [PubMed: 12114546]
- Jaillais Y, Hothorn M, Belkhadir Y, Dabi T, Nimchuk ZL, Meyerowitz EM, Chory J. Tyrosine phosphorylation controls brassinosteroid receptor activation by triggering membrane release of its kinase inhibitor. *Genes Dev*. 2011; 25:232–237. [PubMed: 21289069]
- Kim HH, Vijapurkar U, Hellyer NJ, Bravo D, Koland JG. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. *Biochem J*. 1998; 334(Pt 1):189–195. [PubMed: 9693119]
- Kim TW, Guan S, Sun Y, Deng Z, Tang W, Shang J, Sun Y, Burlingame AL, Wang ZY. Brassinosteroid signal transduction from cell-surface receptor kinases to nuclear transcription factors. *Nat Cell Bio*. 2009; 11:1254–1260. [PubMed: 19734888]
- Kim TW, Wang ZY. Brassinosteroid Signal Transduction from Receptor Kinases to Transcription Factors. *Annu Rev Plant Biol*. 2010; 61:681–704. [PubMed: 20192752]
- Kinoshita T, Cano-Delgado A, Seto H, Hiranuma S, Fujioka S, Yoshida S, Chory J. Binding of brassinosteroids to the extracellular domain of plant receptor kinase BRI1. *Nature*. 2005; 433:167–171. [PubMed: 15650741]
- Li J. Multi-tasking of somatic embryogenesis receptor-like protein kinases. *Curr Opin Plant Biol*. 2010; 13:509–514. [PubMed: 20926334]
- Li J, Chory J. A putative leucine-rich repeat receptor kinase involved in brassinosteroid signal transduction. *Cell*. 1997; 90:929–938. [PubMed: 9298904]
- Li J, Nagpal P, Vitart V, McMorris TC, Chory J. A role for brassinosteroids in light-dependent development of Arabidopsis. *Science*. 1996; 272:398–401. [PubMed: 8602526]
- Li J, Nam KH. Regulation of brassinosteroid signaling by a GSK3/SHAGGY-like kinase. *Science*. 2002; 295:1299–1301. [PubMed: 11847343]
- Li J, Wen J, Lease KA, Doke JT, Tax FE, Walker JC. BAK1, an Arabidopsis LRR receptor-like protein kinase, interacts with BRI1 and modulates brassinosteroid signaling. *Cell*. 2002; 110:213–222. [PubMed: 12150929]
- Lu D, Wu S, Gao X, Zhang Y, Shan L, He P. A receptor-like cytoplasmic kinase, BIK1, associates with a flagellin receptor complex to initiate plant innate immunity. *Proc Natl Acad Sci U S A*. 2009; 107:496–501. [PubMed: 20018686]
- Mora-Garcia S, Vert G, Yin Y, Cano-Delgado A, Cheong H, Chory J. Nuclear protein phosphatases with Kelch-repeat domains modulate the response to brassinosteroids in Arabidopsis. *Genes Dev*. 2004; 18:448–460. [PubMed: 14977918]
- Muto H, Yabe N, Asami T, Hasunuma K, Yamamoto KT. Overexpression of constitutive differential growth 1 gene, which encodes a RLCKVII-subfamily protein kinase, causes abnormal differential and elongation growth after organ differentiation in Arabidopsis. *Plant Physiol*. 2004; 136:3124–3133. [PubMed: 15466232]
- Nam KH, Li J. BRI1/BAK1, a receptor kinase pair mediating brassinosteroid signaling. *Cell*. 2002; 110:203–212. [PubMed: 12150928]
- Shiu SH, Karlowski WM, Pan R, Tzeng YH, Mayer KF, Li WH. Comparative analysis of the receptor-like kinase family in Arabidopsis and rice. *Plant Cell*. 2004; 16:1220–1234. [PubMed: 15105442]
- Sugiyama N, Nakagami H, Mochida K, Daudi A, Tomita M, Shirasu K, Ishihama Y. Large-scale phosphorylation mapping reveals the extent of tyrosine phosphorylation in Arabidopsis. *Mol Syst Biol*. 2008; 4:193. [PubMed: 18463617]
- Sun Y, Fan XY, Cao DM, He K, Tang W, Zhu JY, He JX, Bai MY, Zhu S, Oh E, et al. Integration of Brassinosteroid Signal Transduction with the Transcription Network for Plant Growth Regulation in Arabidopsis. *Dev Cell*. 2010; 19:765–777. [PubMed: 21074725]
- Tang W, Kim TW, Osés-Prieto JA, Sun Y, Deng Z, Zhu S, Wang R, Burlingame AL, Wang ZY. BSKs mediate signal transduction from the receptor kinase BRI1 in Arabidopsis. *Science*. 2008; 321:557–560. [PubMed: 18653891]

- Tang W, Yuan M, Wang R, Yang Y, Wang C, Osés-Prieto JA, Kim TW, Zhou HW, Deng Z, Gampala SS, et al. PP2A activates brassinosteroid-responsive gene expression and plant growth by dephosphorylating BZR1. *Nat Cell Bio.* 2011; 13:124–131. [PubMed: 21258370]
- Tor M, Lotze MT, Holton N. Receptor-mediated signalling in plants: molecular patterns and programmes. *J Exp Bot.* 2009; 60:3645–3654. [PubMed: 19628572]
- Vert G, Chory J. Downstream nuclear events in brassinosteroid signalling. *Nature.* 2006; 441:96–100. [PubMed: 16672972]
- Wang X, Chory J. Brassinosteroids regulate dissociation of BKII, a negative regulator of BRI1 signaling, from the plasma membrane. *Science.* 2006; 313:1118–1122. [PubMed: 16857903]
- Wang X, Kota U, He K, Blackburn K, Li J, Goshe MB, Huber SC, Clouse SD. Sequential transphosphorylation of the BRI1/BAK1 receptor kinase complex impacts early events in brassinosteroid signaling. *Dev Cell.* 2008; 15:220–235. [PubMed: 18694562]
- Wang ZY, Nakano T, Gendron J, He J, Chen M, Vafeados D, Yang Y, Fujioka S, Yoshida S, Asami T, Chory J. Nuclear-localized BZR1 mediates brassinosteroid-induced growth and feedback suppression of brassinosteroid biosynthesis. *Dev Cell.* 2002; 2:505–513. [PubMed: 11970900]
- Wang ZY, Seto H, Fujioka S, Yoshida S, Chory J. BRI1 is a critical component of a plasma-membrane receptor for plant steroids. *Nature.* 2001; 410:380–383. [PubMed: 11268216]
- Yin Y, Vafeados D, Tao Y, Yoshida S, Asami T, Chory J. A new class of transcription factors mediates brassinosteroid-regulated gene expression in Arabidopsis. *Cell.* 2005; 120:249–259. [PubMed: 15680330]
- Yin Y, Wang ZY, Mora-Garcia S, Li J, Yoshida S, Asami T, Chory J. BES1 accumulates in the nucleus in response to brassinosteroids to regulate gene expression and promote stem elongation. *Cell.* 2002; 109:181–191. [PubMed: 12007405]
- Yu X, Li L, Zola J, Aluru M, Ye H, Foudree A, Guo H, Anderson S, Aluru S, Liu P, et al. A brassinosteroid transcriptional network revealed by genome-wide identification of BES1 target genes in Arabidopsis thaliana. *Plant J.* 2011; 65:634–646. [PubMed: 21214652]
- Zhang J, Li W, Xiang T, Liu Z, Laluk K, Ding X, Zou Y, Gao M, Zhang X, Chen S, et al. Receptor-like cytoplasmic kinases integrate signaling from multiple plant immune receptors and are targeted by a Pseudomonas syringae effector. *Cell Host Microbe.* 2010; 7:290–301. [PubMed: 20413097]




### Figure 1. CDG1 Positively Regulates BR Signaling

(A–C) Three independent *35S::CDG1-YFP* transgenic lines are marked as number 1 to 3. Seedlings were grown in the dark for 5 days (A) or for 3-weeks in the light (B), and the expression levels of CDG1-YFP in plants shown in panel (B) was detected by immunoblotting using anti-GFP antibody (C). Upper and middle panels of panel C, respectively, show short and long exposure, and the bottom panel shows a non-specific band as loading control.

(D) Hypocotyl length of wild-type (Col-0), CDG1 overexpression plant (*CDG1-ox*) and *bZR1-1D* seedlings grown in the dark for 5 days on MS medium supplemented with mock solution (Mock) or 2  $\mu$ M BRZ. Error bars are  $\pm$  SEM.

(E) RNA levels of *DWF4* and *SAUR-AC1* were analyzed by quantitative real time-PCR in Col-0 and *CDG1-ox* plant. Error bars are  $\pm$  SEM.

(F) CDG1 overexpression causes accumulation of dephosphorylated BZR1. Upper panel shows the phenotype of transgenic plants expressing BZR1-CFP or *bZR1-1D*-CFP from the BZR1 promoter and overexpressing CDG1. Lower panel shows immunoblot analysis of BZR1-CFP using anti-YFP antibody. Ponceau S staining of the blot is shown as loading control.



**Figure 2. Subcellular Localization, Tissue-Specific Expression and Phenotype of Knockout Mutant of CDG1 and Its Homolog, CDL1**


(A) Plasma membrane localization of CDG1-YFP anchored by palmitoylation. Amino acid sequence of the N-terminal region of CDG1 shows the two cysteine residues (bold) as putative palmitoylation sites. Confocal images show localization of CDG1-YFP or CDG1-C4,6A-YFP in leaf epidermal cells of transgenic *Arabidopsis*. A CDG1-YFP sample was treated with 200 nM BL for 30 min.

(B) Mis-localized CDG1 failed to activate BR signaling. Seedlings of wild-type Col-0 and transgenic plant expressing CDG1-YFP or CDG1-C4,6A-YFP were grown in the dark for 5 days on MS medium with or without 2  $\mu$ M BRZ.

(C) Gene expression pattern of CDG1 and CDL1. GUS staining images show expression of the CDG1 promoter-GUS and CDL1 promoter-GUS in transgenic plants. From left to right are 5-day-old seedling, flowering buds, stamen and stamen filament, pollen, and immature seeds.

(D) BR sensitivity of *cdg1-2*, *cdl1-1*, and *cdg1-2/cdl1-1* mutant. Seedlings were grown under light for 5 days on MS medium containing indicated concentration of brassinolide (BL). Error bars are  $\pm$  SEM.


(E) BRZ sensitivity of *cdg1-2*, *cdl1-1*, and *cdg1-2/cdl1-1* mutant. Seedlings were grown in the dark for 5 days on MS or 2  $\mu$ M BRZ medium, and hypocotyl lengths were measured. Asterisk,  $P < 0.0001$ . Error bars are  $\pm$  SEM.



**Figure 3. Phenotypes Caused by CDG1 Overexpression in Various Genetic Backgrounds**  
 (A–B) Overexpression of CDG1 partially suppresses the dwarf phenotype of *bri1-116* (A) but not *bin2-1* (B). Plants were grown for 7 week. Inset of panel A shows phenotype of 4-week-old plants.

(C–E) Overexpression of *CDG1* and *BSU1* causes similar phenotypes and is synergistic. Both CDG1-ox and BSU1-ox plants display bending in stem-branch junction region (C), flatten and rectangle shape of silique (D), pale-green leaves (E), and slightly reduced sensitivity to BRZ (F). Plants overexpressing both CDG1-YFP and BSU1-myc show enhanced phenotypes (E, F). (F) Seedlings were grown in the dark for 5 days on MS medium with or without 2  $\mu$ M BRZ.






**Figure 4. CDG1 Interacts with BSU1 in vitro and in vivo**

(A) A gel blot separating GST and GST-CDG1 was probed with MBP-BSU1 followed by anti-MBP-HRP antibody. Ponceau S staining shows the total protein on blot.

(B) Yeast two-hybrid assay between CDG1 or CDL1, and BSU1 or BSL1. Pairs of indicated bait (BD) and prey (AD) vectors were transformed into yeast cells. Yeast growth on the SD-His medium indicates interaction.

(C) BiFC assays of in vivo interactions between CDG1 or CDL1 and BSU1 or BSL1. The indicated constructs were co-transformed into tobacco leaf epidermal cells. Bright spots are auto-fluorescence derived from chloroplast.

(D) Co-immunoprecipitation of CDG1 and BSU1. Leaves of transgenic plants co-expressing CDG1-YFP and BSU1-myc were treated with mock solution or 200 nM BL for 30 min. The CDG1-YFP proteins were immunoprecipitated with anti-GFP antibody, and the immunoblot was probed with anti-myc and anti-GFP antibody. Numbers indicate relative BSU1-myc signal level normalized to the CDG1-YFP signal.



### Figure 5. CDG1 Specifically Phosphorylates the Serine 764 Residue of BSU1


(A) CDG1 phosphorylates BSU1 but not the BSU1 homologs in vitro. MBP or MBP fused BSU1, BSL1, BSL2 and BSL3 were incubated with GST-CDG1 and  $^{32}\text{P}$ - $\gamma$ -ATP. Upper panel shows autoradiography and bottom panel Coomassie brilliant blue-staining of the gel. (B) Total protein of BSU1-myc transgenic plants treated with mock solution (-BL) or 200 nM BL (+BL) for 30 min were analyzed by two-dimensional electrophoresis followed by immunoblotting using anti-myc antibody. (C) Identification of three in vivo phosphorylation sites of BSU1. Phosphopeptide sequences identified by LC-MS/MS analysis of BSU1-YFP immunoprecipitated from transgenic plants using anti-GFP antibody.

(D) In vitro kinase assay shows CDG1 phosphorylates a serine 764 residue of BSU1. Equal amount of MBP fused BSU1, BSU1-S395A, BSU1-S444A and BSU1-S764A was incubated with GST-CDG1 and  $^{32}\text{P}$ - $\gamma$ -ATP. Upper panel shows autoradiography and bottom, Coomassie brilliant blue (CBB)-stained gel.

(E) BSU1 phosphorylated by CDG1 more effectively binds to BIN2 in vitro. A gel blot separating MBP fusion proteins of the kinase domains of BRI1 (MBP-BRI1-K), MBP, MBP-BSU1, or MBP-BSU1-S764A, and MBP-BSU1 or MBP-BSU1-S764A pre-incubated with GST-CDG1 and ATP, was sequentially probed with GST-BIN2 and anti-GST antibody. Asterisks indicate the signal derived from GST-CDG1. Numbers indicate relative signal level normalized to the CBB staining of MBP-BSU1.

(F) CDG1 phosphorylation of BSU1 increases BSU1 activity of dephosphorylating BIN2. MBP-BSU1 or MBP-BSU1-S764A immobilized on amylose beads were pre-incubated with GST or GST-CDG1. The beads were washed and further incubated with GST-BIN2. Dephosphorylation of Tyr200 residue of BIN2 was detected by immunoblotting using the anti-tyrosine 279/216 GSK3 $\alpha/\beta$  (anti-pTyr) antibody. The blot was also stained with Ponceau S to show protein loading. Numbers indicate relative signal levels normalized to the loading control.

(G) Phenotypic frequency of transgenic *bri1-5* overexpressing wild-type BSU1 or BSU1-S764A. Total 321 and 264 T1 transgenic plants were counted, respectively.



### Figure 6. BRI1 Interacts with and Phosphorylates CDG1

(A) BiFC assay of BRI1-CDG1 interaction. Tobacco leaf epidermal cells were transformed with indicated constructs. An LRR-RLK (At5g49760) unrelated to BR signaling was used as a negative control. Bright spots are auto-fluorescence from chloroplast.


(B) Co-immunoprecipitation between BRI1-GFP and CDG1-myc. BRI1-GFP was immunoprecipitated with anti-GFP antibody from transgenic *Arabidopsis* expressing CDG1-myc or coexpressing CDG1-myc and BRI1-GFP, and the gel blot was probed with anti-myc and anti-GFP antibodies.

(C) BRI1 kinase domain (BRI1-K), but not BAK1 kinase domain (BAK1-K), strongly phosphorylates CDG1 in vitro. Kinase-inactive mutant proteins (mBRI1, mBAK1 and mCDG1) were phosphorylated by the indicated wild-type kinases using  $^{32}\text{P}$ - $\gamma$ -ATP. Upper panel is autoradiography image, and low panel shows the gel stained by CBB.

(D) BRI1 phosphorylates three serine residues of CDG1 in vitro. Kinase-inactive GST-CDG1-Y147G was incubated with GST-BRI1-K and subjected to trypsin digestion followed by LC-MS/MS analysis. The percentage in parenthesis indicates relative abundance of phospho-peptide containing phospho-serine 44 and phospho-serine 47 residues.

(E) BRI1 phosphorylation of CDG1 is significantly reduced by S44,47A and S234A mutations of CDG1. Upper panel shows autoradiography and lower panel CBB-stained gel. Numbers indicate relative signal level of phosphorylation normalized to loading control.

(F) Phenotypic frequency of 172, 139 and 351 T1 transgenic *bri1-5* plants overexpressing wild-type CDG1, CDG1-S44,47A, or CDG1-S234A, respectively. The categories of phenotypes were classified based on the phenotype 1, 2, and 3, respectively, as indicated in Figure 1B.



**Figure 7. BRI1 Regulation of BIN2 Tyr200 Dephosphorylation in vitro through CDG1 or BSK1 and BSU1**

(A) BRI1 phosphorylation of CDG1 promotes CDG1 binding to BSU1 in vitro. A gel blot separating GST, GST-CDG1 and GST-CDG1 pre-incubated with GST-BRI1-K and ATP was sequentially probed with MBP-BSU1 and anti-MBP antibody, and re-probed with anti-GST antibody. Asterisk (\*) indicates GST-BRI1.

(B) Pre-incubation of CDG1 and BRI1 enhances CDG1 phosphorylation of BSU1 in vitro. GST-CDG1 was pre-incubated with MBP or MBP-BRI1 in the kinase buffer, and then recovered by glutathione beads. Equal amount of the beads was incubated with MBP-BSU1 and  $^{32}\text{P}$ - $\gamma$ -ATP, and the proteins analyzed by SDS PAGE and autoradiography after CBB staining.

(C) BRI1 promotes BSU1 dephosphorylation of BIN2 in the presence of CDG1 and BSK1 in vitro. GST-CDG1, GST-BSK1, GST-BRI1-K, and GST-mBRI1-K were pre-incubated with MBP or MBP-BSU1 in the presence of ATP for 1.5 hour, and then BIN2 protein was added and further incubated. The gel blot was sequentially probed with anti-pTyr297/216 GSK3 $\alpha/\beta$  antibody and anti-BIN2 antibody, and the ratios between the two signals were quantified as level of Tyr200 phosphorylation. Double asterisk (\*\*) indicates a significant difference ( $P < 0.08$ ). Error bars are  $\pm$  SEM.